TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 or above~* Congestive Heart Failure with symptoms for more than 4 weeks before starting study~* Provision of informed consent~Exclusion Criteria:~* Current low blood pressure with symptoms~* Liver disease considered significant by the study doctor~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk peptic ulcers bleeding (Forrest class Ia,Ib,IIa,IIb)~Exclusion Criteria:~* Patients were not achieve endoscopic hemostasis~* End stage cancer disease~* Severe critical illness and ICU setting~* Uncorrectable coagulopathy~* Pregnancy or breast feeding~* Allergy to PPIs or Vonoprazan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vonoprazan (Type: EXPERIMENTAL): Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
- PPIs (Type: ACTIVE_COMPARATOR): PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older.~* Histologically confirmed, relapsed or refractory, follicular B-cell non-Hodgkin lymphoma (NHL) (follicular lymphoma) Grade 1, 2, and 3a.~* Ineligible for hematopoietic stem cell transplant.~* Must have been treated with at least 2 prior systemic therapies.~* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the longest dimension and ≥ 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.~* Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.~Exclusion Criteria:~* Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.~* History of central nervous system lymphoma (either primary or metastatic).~* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan-PI3K inhibitor.~* Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).~* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.~* Active graft-versus-host disease.~* Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
- Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic Manual, fourth edition (DSM-IV).~* Agree to participate in the study and provide informed consent.~Exclusion Criteria:~* Meet DSM-IV criteria of major mood disorder, current substance dependence or mental retardation~* History of epilepsy, head trauma or CNS diseases~* Major, untreated medical diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Role Against Chemotherapy-induced Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients\> 18 years old.~* Female patients Breast cancer patients who received paclitaxel-based regimen for 12 weeks.~* Eastern Cooperative Oncology Group (ECOG) performance ≤ 2-Adequate bone marrow function.~* Adequate liver and kidney function.~Exclusion Criteria:~* Children less than 18 years old.~* Evidence of physical diseases or major surgery.~* Patientswith a history of chronic diseases including; renal, hepatic, gastrointestinal, respiratory, hematological, and metabolic or other diseases.~* Patients with preexisting clinical neuropathy.~* Patients with diabetes mellitus.~* Metastatic breast cancer.~* Patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics.~* Patients treated with medications that increase the risk of neuropathy.~* Hypersensitivity to pentoxifylline or xanthine derivatives.~* Patients retinal bleeding or active peptic ulcer.~* Patients at high risk for bleeding or taking medications that increase risk of bleeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PTX group (Type: ACTIVE_COMPARATOR): paclitaxel based regimens plus Pentoxifylline 400mg twice daily for 12weeks.
- Control group (Type: PLACEBO_COMPARATOR): include those assigned for Taxol-based chemotherapy without intervention for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 65 years of age, scheduled for hernia repair surgery~* Patients must be in good health prior to study participation~* Patients must have blood pressure within normal range or with Stage 1 high blood pressure~* Male and female patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial is completed~* Patients must refrain from strenuous activities and avoid changes to prescribed exercise levels throughout the course of the trial~* Ability to read, understand, communicate, and voluntarily sign the informed consent form prior to any trial specific procedures~Exclusion Criteria:~* Patients with previous abdominal surgery scar tissue~* Patients with clinically significant abnormalities of any body system unrelated to the disease under study~* Connective tissue disorders~* Patients who are pregnant or lactating~* Current or regular use of analgesic medication for other indications~* Patients with current or regular use of antidepressants or monoamine oxidase inhibitors at screening~* Use of any drugs or medication that may interfere with the study and its results~* Patients with known hypersensitivity to the study drugs or their components~* Patients with known or suspected alcohol abuse or illicit drug use~* Participation in another clinical trial at the same time or within 30 days of this trial~* Patient is unwilling to comply with the study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: SABER-Bupivacaine (Type: EXPERIMENTAL): 2.5 mL SABER-Bupivacaine/Once
- Group 2: SABER-Bupivacaine (Type: EXPERIMENTAL): 5.0 mL SABER-Bupivacaine/Once
- Group 3: SABER-Placebo (Type: PLACEBO_COMPARATOR): 2.5 mL or 5.0 mL SABER-Placebo/Once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a primary diagnosis of ADHD~* Subject must be adequately controlled on a stable dose of one of the following medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not to exceed 54 mg per day~* Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin pregnancy test~Exclusion Criteria:~* A history of mental retardation that would indicate that the subject is not functioning at an age appropriate level intellectually~* A recent history of suspected substance abuse or dependence disorder~* Subject is taking Strattera~* Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
- Placebo patch (Type: PLACEBO_COMPARATOR): Placebo patch applied daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be at least 40 years old~* Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory.~* High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes).~* Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.~  * lipid-lowering drugs~ * testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone~* Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.~* Males who agree to use highly effective or effective methods of contraception may participate in this trial.~* Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial.~Exclusion Criteria:~* Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.~* Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:~  * major surgery~ * coronary, carotid, or peripheral arterial revascularization~ * stroke or transient ischemic attack~ * myocardial infarction or unstable angina~ * acute limb ischemia~* Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes~* Have uncontrolled hypertension

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3473329 Dose 1 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- LY3473329 Dose 2 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- LY3473329 Dose 3 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18 years and older.~* Hypertension patients have not received any anti-hypertensive treatment before ( ≥ 140 mmHg MSSBP \< 160 mmHg, ≥ 90 mmHg MSDBP \< 100mmHg).~* Hypertension patients controlled with single medicine.~* Patients giving written informed consent without being under any influence.~Exclusion Criteria:~* Pregnant patients, nursing mothers or female patients who have potential for childbearing and do not use any effective contraceptive method.~* Allergy or hypersensitivity to dihydropyridines.~* Patients receive more than one anti-hypertensive medicine.~* Patients with seconder hypertension.~* Patients with severe hypertension, myocardial infarction, NYHA stage 2-4 cardiac insufficiency, history of cerebrovascular disease, past ischemic attack, encephalopathy, underwent coronary artery bypass surgery or percutaneous coronary intervention, second or third degree heart block or symptomatic arrhythmia without pacemaker, clinically significant heart valve disease, potential life-threatening or symptomatic arrhythmia, simultaneous unstable angina pectoris, type I diabetes mellitus, atrial fibrillation until the last 12 months.~* Uncontrolled type II diabetes mellitus.~* Patients with significant liver disease (ALT, AST must be \> 2XULN in beginning, patients with esophageal varices, portacaval shunt).~* Patients with significant kidney disease (GFR \<60 ml/min according to Cockcroft-Gault formula).~* Patients with volume depletion.~* Patients with pancreas disease.~* Patients with gastrointestinal disease which may effect absorption.~* Drug/narcotic and alcohol abuse until the last 12 months.~* Patients with central nervous system disease and taking medicine for this reason.~* History of incompatibility with medical regimes or patients do not want to adhere the study protocol.~* Persons directly involved in the management of this protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- s-amlodipine besylate 2,5 and 5 mg tablets (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Women: non-pregnant, non-lactating; if of childbearing potential, on specified contraception measures during the study period~* Men: using barrier contraception measures during the study period~Exclusion Criteria:~* Health conditions~* Taking prescription and non-prescription drugs (exceptions: acetaminophen, vitamins, hormonal birth control)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 - 3 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 3 mg oral solution or placebo
- Cohort 2 - 10 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 10 mg oral solution or placebo
- Cohort 3- 30 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 30 mg oral solution or placebo
- Cohort 4 - 90 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 90 mg oral solution or placebo
- Cohort 5 - 180 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 180 mg oral solution or placebo
- Cohort 6 - 360 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 360 mg oral solution or placebo
- Cohort 7 - 720 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 720 mg oral solution or placebo
- Cohort 8 - 1000 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 1000 mg oral solution or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee or hip which requires treatment with a medication to obtain pain relief~Exclusion Criteria:~* Any known allergy to the study drugs

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients (\>68 and \<82 years) with atrial fibrillation and adequate oral anticoagulation therapy and cholesterol levels between 4,5 mmol/l and 7 mmol/l~Exclusion Criteria:~* Indication for cholesterol lowering treatment according to Dutch CBO-cholesterol guidelines (2004)

- Gender: ALL
- Minimum Age: 68 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as schizophrenia by DSM-IV-TR criteria both in inpatients~* Patients who are symptomatically stable, as judged by the treating psychiatrist, and receive a stable dose of risperidone for a minimum of 2 weeks before enrollment.~* Patients with ability to complete various questionnaires.~* Patients and/or their legal guardians/representatives who sufficiently understand the objective of the study and sign informed consent form~Exclusion Criteria:~* Active psychotic symptoms, including severe behavioral disturbance~* Relevant history of or current presence of any significant or unstable medical disease~* A woman who is pregnant, breast-feeding or planning to become pregnant during the study period~* Patients with the history of serious allergy or multiple adverse drug reactions~* Patients with the history of taking paliperidone ER within 60 days~* Patients with history of taking clozapine within 60 days~* Patients who require the treatment of other medications influencing CNS, except permitted concomitant drugs in advance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- 1. Paliperidone ER (Type: EXPERIMENTAL): New antipsychotics
- 2 Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete